HENDERSON, NV / ACCESSWIRE / October 18, 2018 / October is Liver Cancer Awareness month. According to the American Cancer Society, liver cancer incidence has more than tripled since 1980, liver cancer death rates have increased by almost 3% per year since 2000 and more than 700,000 people are diagnosed with liver cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year.
One company that is working toward investigating this growing issue is, Delcath Systems, Inc. (DCTH), the company has initiated a global phase 3 clinical trial in patients with intrahepatic cholangiocarcinoma (ICC), using its product Melphalan/HDS.
The company recently announced several major cancer centers have adopted the amended trial protocol for patients enrolling in the company's Hepatic-Dominant Ocular Melanoma (The FOCUS Trial).
Companies we're highlighting include: Delcath Systems, Inc. (DCTH), Cronos Group Inc. (CRON), Aurora Cannabis, Inc. (ACBFF), Verastem, Inc. (VSTM), and Neptune Wellness Solutions, Inc. (NEPT).
Delcath Systems, Inc. (DCTH)
Market Cap: $5.21M Share Price: $0.90
Delcath Systems, Inc. (DCTH), just announced that six major cancers in the United States have adopted the amended trial protocol for the company's registration trial in ocular melanoma liver metastases. These centers join Stanford Medical Center in initiating enrollment in the amended trial, giving the company wide geographic cover.
The trial, A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma enrolling a minimum of 80 patients with ocular melanoma metastatic to the liver. The Company expects approximately 30 leading cancer centers in the U.S. and Europe to participate in the amended FOCUS Trial.
Cronos Group Inc. (CRON)
Market Cap: $2.09B Share Price: $12.57
Cronos announced a deal with the Technion Research and Development Foundation of the Technion – Israel Institute of Technology to research the use of cannabinoids in skin diseases.
However, the primary catalyst for today's movement seems to be mounting anticipation of the Canadian recreational marijuana market opening on Wednesday, Oct. 17.
Aurora Cannabis, Inc. (ACBFF)
Market Cap: $10.79B Share Price: $11.23
The company released fiscal fourth-quarter earnings and confirmed its intention to list stock on a "senior" U.S. exchange such as the Nasdaq or the New York Stock Exchange.
Further to this on Friday, October 5, the company filed a Form-40 with the intent of registering its securities on the New York Stock Exchange. Aurora could join the ranks of a growing number of cannabis companies choosing to list on major exchanges in the US. Late last month, Canaccord Genuity raised its price target for Aurora Cannabis to 13 Canadian dollars from 11 Canadian dollars.
Aurora Chief Executive Terry Booth said, "This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success."
Verastem, Inc. (VSTM)
Market Cap: $437.50M Share Price: $5.94
Verastem, Inc., (VSTM) just announced the pricing of an offering of 5.00% Convertible Senior Notes due 2048 (the Convertible Notes) through a registered direct offering. The aggregate principal amount of Convertible Notes to be sold in the offering is $150 million. The Convertible Notes will be unsecured, will bear interest at a rate of 5.00% per annum, paid semi-annually in arrears, and will mature on November 1, 2048, unless earlier converted, redeemed or repurchased in accordance with their terms prior to such date.
Neptune Wellness Solutions, Inc. (NEPT)
Market Cap: $361.34M Share Price: $4.54
NEPT recently appointed Ms. Hélène F. Fortin to its Board of Directors. Hélène F. Fortin FCPA, FCA, ICD.D-IAS.A has been practicing public accounting for more than 30 years. A member of CPA Québec, she lectured in Accounting and Auditing during more than 20 years at many universities in both the undergraduate and graduate levels.
Important Disclaimer, Please Read:
The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.
The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.
Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. DCTH has paid, and continues to pay Regal to disseminate truthful and potentially material information regarding DCTH.
Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.
Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.
Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in DCTH can be found updated here: http://www.regalconsultingllc.com/disclaimer/.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eleven thousand dollars total by Regal Consulting. LLC, for news commentary articles for DCTH. DCTH and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of DCTH in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC,For Full Legal Disclaimer Click
Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communication, LLC